In these cases, 30 patients (14.4%) underwent postoperative chemotherapy (pemetrexed and cisplatin based), 2 patients (1.0%) underwent WBRT, 30 patients (14.4%) underwent molecular targeted therapy (28 patients receiving EGFR tyrosine kinase inhibitors (TKIs) and 2 patients ALK TKIs), 4 patients (2.0%) received chemotherapy combined with WBRT, 6 patients (2.9%) underwent lung cancer resection combined with chemotherapy. This evidence concerns the gene ALK and lung cancer.